Obesity. Obesity due to excess calories
Conditions
Interventions
Intervention 1: Intervention group 1: a 50000 IU vitamin D tablet (Zahravi, Iran), weekly+ a magnesium tablet (each tablet containing 250 mg magnesium in the form of magnesium oxide) (Jalinous, Iran),
Sponsors
National Institute for Medical Research Development
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Obese women with BMI range of 30-40 kg/m2 Aged 18-50 years Serum 25(OH)D < 30 ng/ml No autoimmune disease, renal, hepatic, parathyroid, and gastrointestinal disorders No taking vitamin D and/or magnesium supplements or anti-depressant and anti-inflammatory drugs
Exclusion criteria
Exclusion criteria: Affecting by any acute disease during the study Unwillingness to continue the study Less than 90% compliance with the treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of TNF-a. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum TNF-a levels will be assessed by ELISA and Bender Med kit (Bender Med, Germany). | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum level of IL-6. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum IL-6 levels will be assessed by ELISA and Bender Med kit (Bender Med, Germany).;Serum level of BDNF. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum BDNF levels will be assessed by ELISA and ZellBio kit (ZellBio, Germany).;Serum level of SIRT-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum SIRT-1 levels will be assessed by ELISA and ZellBio kit (ZellBio, Germany).;Mood. Timepoint: Before and 8 weeks after intervention. Method of measurement: Beck Depression Inventory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammadreza Vafa
Iran University of Medical Sciences
Outcome results
None listed